L
Linda T. Vahdat
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 251
Citations - 14180
Linda T. Vahdat is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Breast cancer & Metastatic breast cancer. The author has an hindex of 55, co-authored 241 publications receiving 11976 citations. Previous affiliations of Linda T. Vahdat include American Society of Clinical Oncology & NewYork–Presbyterian Hospital.
Papers
More filters
Journal ArticleDOI
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
Kari R. Fischer,Anna Durrans,Sharrell Lee,Jianting Sheng,Fuhai Li,Stephen T. C. Wong,Hyejin Choi,Tina El Rayes,Seongho Ryu,Seongho Ryu,Juliane S. Troeger,Robert F. Schwabe,Linda T. Vahdat,Nasser K. Altorki,Vivek Mittal,Dingcheng Gao +15 more
TL;DR: The potential of an EMT-targeting strategy, in conjunction with conventional chemotherapies, for breast cancer treatment is suggested, using a mesenchymal-specific Cre-mediated fluorescent marker switch system in spontaneous breast-to-lung metastasis models.
Journal ArticleDOI
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study
Javier Cortes,Joyce O'Shaughnessy,David Loesch,Joanne L. Blum,Linda T. Vahdat,Katarina Petrakova,Philippe Chollet,Alexey Manikas,Véronique Diéras,Thierry Delozier,Vladimir Vladimirov,Fatima Cardoso,Han Koh,Philippe Bougnoux,Corina E. Dutcus,Seth Seegobin,Denis Mir,Nicole Meneses,Jantien Wanders,Chris Twelves +19 more
TL;DR: Eribulin showed a significant and clinically meaningful improvement in overall survival compared with TPC in women with heavily pretreated metastatic breast cancer, challenging the notion that improved overall survival is an unrealistic expectation during evaluation of new anticancer therapies in the refractory setting.
Journal ArticleDOI
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
Aditya Bardia,Ingrid A. Mayer,Linda T. Vahdat,Sara M. Tolaney,Steven J. Isakoff,Jennifer R. Diamond,Joyce O'Shaughnessy,Rebecca L. Moroose,Alessandro D. Santin,Vandana G. Abramson,Nikita C. Shah,Hope S. Rugo,David M. Goldenberg,Ala M Sweidan,Robert Iannone,Sarah A. Washkowitz,Robert M. Sharkey,William A. Wegener,Kevin Kalinsky +18 more
TL;DR: It is shown that sacituzumab govitecan‐hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple‐negative breast cancer and was also associated with clinical benefit rate and overall survival.
Journal ArticleDOI
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
Eva Thomas,Henry L. Gomez,Rubi K. Li,Hyun Cheol Chung,Luis Fein,Valorie F. Chan,Jacek Jassem,Xavier Pivot,J. Klimovsky,Fernando Hurtado de Mendoza,Binghe Xu,Mario Campone,Guillermo Lerzo,Ronald Peck,Pralay Mukhopadhyay,Linda T. Vahdat,Henri Roché +16 more
TL;DR: Ixabepilone plus capecitabine demonstrates superior efficacy to cape citabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes.
Journal ArticleDOI
Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine
Edith A. Perez,Guillermo Lerzo,Xavier Pivot,Eva Thomas,Linda T. Vahdat,Linda D. Bosserman,Patrice Viens,Can Cai,Brian Mullaney,Ronald Peck,Gabriel N. Hortobagyi +10 more
TL;DR: Ixabepilone demonstrated clear activity and a manageable safety profile in patients with MBC resistant to anthracycline, taxane, and capecitabine, and Responses were durable and notable in patients who had not previously responded to multiple prior therapies.